Latest News
Lilly's Taltz and Zepbound combination delivers sustained psoriatic arthritis improvements at one year
11 November 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) on Wednesday reported 52-week Phase 3b results showing sustained improvements in disease activity, physical function and metabolic outcomes when Taltz (ixekizumab) and Zepbound (ti...
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
11 November 2026 - Precision oncology company Guardant Health Inc (Nasdaq: GH) announced on Wednesday that it has expanded its Guardant360 Liquid cancer testing capabilities with new epigenomic applications designed to improve treatment selection in ...
Ascletis announces submission of US IND application for oral obesity combination therapy
11 November 2026 - Biotechnology company Ascletis Pharma Inc (HKEX: 1672) reported on Wednesday that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration for ASC30_39 FDC, a once-daily oral fixed-dose ...
Jubilant Therapeutics to present LSD1 and HDAC6 (CoREST) orally administered dual inhibitor Phase 1/2 study results at 68th ASH Annual Meeting
11 November 2026 - Jubilant Therapeutics Inc, a US-based, clinical-stage biopharmaceutical company that is advancing precision therapeutics for myeloproliferative neoplasms (MPNs), announced on Tuesday that clinical results from its Phase 1/2 study o...
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
11 November 2026 - Nuvation Bio Inc (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Tuesday that David Hung, MD, founder, president, and chief executive officer of Nuvation Bio, and Philippe Sauvage, ...